MovDisordV3, Main, Exploration, bibRecord, 005909

Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus

Identifieur interne : 005909 ( Main/Exploration ); précédent : 005908; suivant : 005910

Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus

Auteurs : Rae R. Matsumoto [États-Unis] ; Matthew J. Hussong [États-Unis] ; Truong [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1995-09.

RBID : ISTEX:A1CB08F7F73025563A23660028278804CE82EBCD

Descripteurs français

Pascal (Inist)
- Animal, Hypoxie, Modèle animal, Myoclonie, Oxygène, Physiopathologie, Rat, Récepteur sérotoninergique.
Wicri :
- topic : Oxygène.

English descriptors

KwdEn :
- (±)‐2,5‐Dimethoxy‐4‐iodoamphetamine hydrobromide, Animal, Animal model, Animals, Anoxia (complications), Behavior, Animal (drug effects), Brain Stem (drug effects), Brain Stem (physiopathology), Heart Arrest (complications), Hypoxia, Ischemia, Male, Myoclonus, Myoclonus (drug therapy), Myoclonus (etiology), Oxygen, Pathophysiology, Rat, Rats, Rats, Sprague-Dawley, Receptors, Serotonin (drug effects), Serotonin, Serotonin Agents (pharmacology), Serotonin Agents (therapeutic use), Serotoninergic receptor, Synaptic Transmission (drug effects), l‐(m‐Chlorophenyl)‐biguanide hydrochloride.
MESH :
- chemical , drug effects : Receptors, Serotonin.
- complications : Anoxia, Heart Arrest.
- drug effects : Behavior, Animal, Brain Stem, Synaptic Transmission.
- drug therapy : Myoclonus.
- etiology : Myoclonus.
- chemical , pharmacology : Serotonin Agents.
- physiopathology : Brain Stem.
- chemical , therapeutic use : Serotonin Agents.
- Animals, Male, Rats, Rats, Sprague-Dawley.

Abstract

Male Sprague‐Dawley rats underwent cardiac arrest and resuscitation, subsequently exhibiting posthypoxic myoclonus. The audiogenic posthypoxic myoclonus in these animals could be attenuated with the following drugs: 5‐hydroxytryptophan (5‐HTP, serotonin [5‐HT] precursor), N‐(3‐trifluoromethylphenyl) piperazine hydrochloride (TFMPP, 5‐HT1B/1C/2 agonist), (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrobromide (DOI, 5‐HT2 agonist), and l‐(m‐chlorophenyl)‐biguanide hydrochloride (m‐CPBG, 5‐HT3 agonist). In contrast, the following drugs were ineffective: (±)‐8‐hydroxy‐dipropylaminottetralin hydrobromide (8‐OH‐DPAT, 5‐HT1A agonist), buspirone hydrochoride (5‐HT1A agonist), 7‐trifluoromethyl‐4(4‐methyl‐1‐piperazinyl)‐pyrrolo[1,2‐a]quinoxaline maleate (CGS 12066B, 5‐HT1B agonist), ketanserin tartrate (5‐HT2 antagonist), methysergide maleate (5‐HT2 antagonist), fluoxetine (5‐HT uptake blocker), and saline (vehicle). The data suggest that enhancement of serotonergic activity, particularly through 5‐HT2 and 5‐HT3 receptors, have therapeutic potential for the treatment of posthypoxic myoclonus.

Url:

https://api.istex.fr/document/A1CB08F7F73025563A23660028278804CE82EBCD/fulltext/pdf

DOI: 10.1002/mds.870100514

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus</title>
<author><name sortKey="Matsumoto, Rae R" sort="Matsumoto, Rae R" uniqKey="Matsumoto R" first="Rae R." last="Matsumoto">Rae R. Matsumoto</name>
</author>
<author><name sortKey="Hussong, Matthew J" sort="Hussong, Matthew J" uniqKey="Hussong M" first="Matthew J." last="Hussong">Matthew J. Hussong</name>
</author>
<author><name sortKey="Truong" sort="Truong" uniqKey="Truong" last="Truong">Truong</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A1CB08F7F73025563A23660028278804CE82EBCD</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100514</idno>
<idno type="url">https://api.istex.fr/document/A1CB08F7F73025563A23660028278804CE82EBCD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001E75</idno>
<idno type="wicri:Area/Istex/Curation">001E75</idno>
<idno type="wicri:Area/Istex/Checkpoint">003D40</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Matsumoto R:effects:of:selective</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8552114</idno>
<idno type="wicri:Area/PubMed/Corpus">004931</idno>
<idno type="wicri:Area/PubMed/Curation">004931</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004988</idno>
<idno type="wicri:Area/Ncbi/Merge">004A52</idno>
<idno type="wicri:Area/Ncbi/Curation">004A52</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A52</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Matsumoto R:effects:of:selective</idno>
<idno type="wicri:Area/Main/Merge">008A71</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:95-0525344</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003457</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003367</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003502</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Matsumoto R:effects:of:selective</idno>
<idno type="wicri:Area/Main/Merge">008B99</idno>
<idno type="wicri:Area/Main/Curation">005909</idno>
<idno type="wicri:Area/Main/Exploration">005909</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus</title>
<author><name sortKey="Matsumoto, Rae R" sort="Matsumoto, Rae R" uniqKey="Matsumoto R" first="Rae R." last="Matsumoto">Rae R. Matsumoto</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson and Movement Disorder Program, Department of Neurology, University of California‐Irvine, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hussong, Matthew J" sort="Hussong, Matthew J" uniqKey="Hussong M" first="Matthew J." last="Hussong">Matthew J. Hussong</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson and Movement Disorder Program, Department of Neurology, University of California‐Irvine, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Truong" sort="Truong" uniqKey="Truong" last="Truong">Truong</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson and Movement Disorder Program, Department of Neurology, University of California‐Irvine, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-09">1995-09</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="615">615</biblScope>
<biblScope unit="page" to="621">621</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A1CB08F7F73025563A23660028278804CE82EBCD</idno>
<idno type="DOI">10.1002/mds.870100514</idno>
<idno type="ArticleID">MDS870100514</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(±)‐2,5‐Dimethoxy‐4‐iodoamphetamine hydrobromide</term>
<term>Animal</term>
<term>Animal model</term>
<term>Animals</term>
<term>Anoxia (complications)</term>
<term>Behavior, Animal (drug effects)</term>
<term>Brain Stem (drug effects)</term>
<term>Brain Stem (physiopathology)</term>
<term>Heart Arrest (complications)</term>
<term>Hypoxia</term>
<term>Ischemia</term>
<term>Male</term>
<term>Myoclonus</term>
<term>Myoclonus (drug therapy)</term>
<term>Myoclonus (etiology)</term>
<term>Oxygen</term>
<term>Pathophysiology</term>
<term>Rat</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Receptors, Serotonin (drug effects)</term>
<term>Serotonin</term>
<term>Serotonin Agents (pharmacology)</term>
<term>Serotonin Agents (therapeutic use)</term>
<term>Serotoninergic receptor</term>
<term>Synaptic Transmission (drug effects)</term>
<term>l‐(m‐Chlorophenyl)‐biguanide hydrochloride</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Serotonin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anoxia</term>
<term>Heart Arrest</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
<term>Brain Stem</term>
<term>Synaptic Transmission</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain Stem</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Male</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animal</term>
<term>Hypoxie</term>
<term>Modèle animal</term>
<term>Myoclonie</term>
<term>Oxygène</term>
<term>Physiopathologie</term>
<term>Rat</term>
<term>Récepteur sérotoninergique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Oxygène</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Male Sprague‐Dawley rats underwent cardiac arrest and resuscitation, subsequently exhibiting posthypoxic myoclonus. The audiogenic posthypoxic myoclonus in these animals could be attenuated with the following drugs: 5‐hydroxytryptophan (5‐HTP, serotonin [5‐HT] precursor), N‐(3‐trifluoromethylphenyl) piperazine hydrochloride (TFMPP, 5‐HT1B/1C/2 agonist), (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrobromide (DOI, 5‐HT2 agonist), and l‐(m‐chlorophenyl)‐biguanide hydrochloride (m‐CPBG, 5‐HT3 agonist). In contrast, the following drugs were ineffective: (±)‐8‐hydroxy‐dipropylaminottetralin hydrobromide (8‐OH‐DPAT, 5‐HT1A agonist), buspirone hydrochoride (5‐HT1A agonist), 7‐trifluoromethyl‐4(4‐methyl‐1‐piperazinyl)‐pyrrolo[1,2‐a]quinoxaline maleate (CGS 12066B, 5‐HT1B agonist), ketanserin tartrate (5‐HT2 antagonist), methysergide maleate (5‐HT2 antagonist), fluoxetine (5‐HT uptake blocker), and saline (vehicle). The data suggest that enhancement of serotonergic activity, particularly through 5‐HT2 and 5‐HT3 receptors, have therapeutic potential for the treatment of posthypoxic myoclonus.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Matsumoto, Rae R" sort="Matsumoto, Rae R" uniqKey="Matsumoto R" first="Rae R." last="Matsumoto">Rae R. Matsumoto</name>
</region>
<name sortKey="Hussong, Matthew J" sort="Hussong, Matthew J" uniqKey="Hussong M" first="Matthew J." last="Hussong">Matthew J. Hussong</name>
<name sortKey="Truong" sort="Truong" uniqKey="Truong" last="Truong">Truong</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005909 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005909 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A1CB08F7F73025563A23660028278804CE82EBCD
   |texte=   Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus

Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.